# Akamai Technologies Inc: financial statements, quarterly

AKAM · Nasdaq · CIK 1086222 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akam.md) · [Financials](/companies/akam/financials.md) · [Filings](/companies/akam/filings.md) · [Insiders](/companies/akam/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/akam/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [965](/filings/0001086222-24-000216.md) | [995 d](/filings/0001086222-26-000022.md) | [987](/filings/0001086222-25-000149.md) | [980](/filings/0001086222-25-000218.md) | [1,005](/filings/0001086222-25-000256.md) | [1,020 d](/filings/0001086222-26-000022.md) | [1,015](/filings/0001086222-26-000058.md) | [1,043](/filings/0001086222-26-000086.md) | [1,055](/filings/0001086222-25-000256.md) | [1,095 d](/filings/0001086222-26-000022.md) | [1,074](/filings/0001086222-26-000058.md) | [1,100](/filings/0001086222-26-000086.md) |
| Cost of revenue | $m | [383](/filings/0001086222-24-000216.md) | [393 d](/filings/0001086222-26-000022.md) | [395](/filings/0001086222-25-000149.md) | [403](/filings/0001086222-25-000218.md) | [409](/filings/0001086222-25-000256.md) | [414 d](/filings/0001086222-26-000022.md) | [419](/filings/0001086222-26-000058.md) | [427](/filings/0001086222-26-000086.md) | [430](/filings/0001086222-25-000256.md) | [453 d](/filings/0001086222-26-000022.md) | [471](/filings/0001086222-26-000058.md) | [486](/filings/0001086222-26-000086.md) |
| Research and development | $m | [106](/filings/0001086222-24-000216.md) | [109 d](/filings/0001086222-26-000022.md) | [117](/filings/0001086222-25-000149.md) | [113](/filings/0001086222-25-000218.md) | [120](/filings/0001086222-25-000256.md) | [120 d](/filings/0001086222-26-000022.md) | [124](/filings/0001086222-26-000058.md) | [126](/filings/0001086222-26-000086.md) | [125](/filings/0001086222-25-000256.md) | [139 d](/filings/0001086222-26-000022.md) | [142](/filings/0001086222-26-000058.md) | [149](/filings/0001086222-26-000086.md) |
| Operating income | $m | [176](/filings/0001086222-24-000216.md) | [185 d](/filings/0001086222-26-000022.md) | [167](/filings/0001086222-25-000149.md) | [148](/filings/0001086222-25-000218.md) | [70.6](/filings/0001086222-25-000256.md) | [148 d](/filings/0001086222-26-000022.md) | [155](/filings/0001086222-26-000058.md) | [151](/filings/0001086222-26-000086.md) | [166](/filings/0001086222-25-000256.md) | [94.9 d](/filings/0001086222-26-000022.md) | [114](/filings/0001086222-26-000058.md) | [80.3](/filings/0001086222-26-000086.md) |
| Interest expense | $m | [5.0](/filings/0001086222-23-000285.md) | [6.9 d](/filings/0001086222-24-000040.md) | [6.8](/filings/0001086222-24-000148.md) | [6.8](/filings/0001086222-25-000218.md) | [6.7](/filings/0001086222-25-000256.md) | [6.7 d](/filings/0001086222-26-000022.md) | [6.8](/filings/0001086222-26-000058.md) | [8.2](/filings/0001086222-26-000086.md) | [7.9](/filings/0001086222-25-000256.md) | [7.9 d](/filings/0001086222-26-000022.md) | [8.3](/filings/0001086222-26-000058.md) | [9.1](/filings/0001086222-26-000086.md) |
| Income tax | $m | [20.3](/filings/0001086222-24-000216.md) | [35.1 d](/filings/0001086222-26-000022.md) | [12.8](/filings/0001086222-25-000149.md) | [35.1](/filings/0001086222-25-000218.md) | [15.9](/filings/0001086222-25-000256.md) | [18.2 d](/filings/0001086222-26-000022.md) | [50.2](/filings/0001086222-26-000058.md) | [48.3](/filings/0001086222-26-000086.md) | [33.0](/filings/0001086222-25-000256.md) | [18.8 d](/filings/0001086222-26-000022.md) | [15.7](/filings/0001086222-26-000058.md) | [20.6](/filings/0001086222-26-000086.md) |
| Net income | $m | [161](/filings/0001086222-24-000216.md) | [161 d](/filings/0001086222-26-000022.md) | [175](/filings/0001086222-25-000149.md) | [132](/filings/0001086222-25-000218.md) | [57.9](/filings/0001086222-25-000256.md) | [140 d](/filings/0001086222-26-000022.md) | [123](/filings/0001086222-26-000058.md) | [104](/filings/0001086222-26-000086.md) | [140](/filings/0001086222-25-000256.md) | [85.1 d](/filings/0001086222-26-000022.md) | [106](/filings/0001086222-26-000058.md) | [79.4](/filings/0001086222-26-000086.md) |
| Diluted EPS | $ per share | [1.04](/filings/0001086222-24-000216.md) | not reported | [1.11](/filings/0001086222-25-000149.md) | [0.86](/filings/0001086222-25-000218.md) | [0.38](/filings/0001086222-25-000256.md) | not reported | [0.82](/filings/0001086222-26-000058.md) | [0.71](/filings/0001086222-26-000086.md) | [0.97](/filings/0001086222-25-000256.md) | not reported | [0.71](/filings/0001086222-26-000058.md) | [0.52](/filings/0001086222-26-000086.md) |
| Basic EPS | $ per share | [1.06](/filings/0001086222-24-000216.md) | not reported | [1.16](/filings/0001086222-25-000149.md) | [0.86](/filings/0001086222-25-000218.md) | [0.38](/filings/0001086222-25-000256.md) | not reported | [0.83](/filings/0001086222-26-000058.md) | [0.72](/filings/0001086222-26-000086.md) | [0.98](/filings/0001086222-25-000256.md) | not reported | [0.73](/filings/0001086222-26-000058.md) | [0.55](/filings/0001086222-26-000086.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.5](/filings/0001086222-24-000216.md) | [0.5](/filings/0001086222-26-000022.md) | [0.5](/filings/0001086222-25-000149.md) | [0.4](/filings/0001086222-25-000218.md) | [0.6](/filings/0001086222-25-000256.md) | [0.5](/filings/0001086222-26-000022.md) | [1.1](/filings/0001086222-26-000058.md) | [0.9](/filings/0001086222-26-000086.md) | [0.9](/filings/0001086222-25-000256.md) | [0.9](/filings/0001086222-26-000086.md) | [0.6](/filings/0001086222-26-000058.md) | [1.5](/filings/0001086222-26-000086.md) |
| Current assets | $bn | [1.9](/filings/0001086222-23-000285.md) | [1.8](/filings/0001086222-25-000028.md) | [2.6](/filings/0001086222-24-000148.md) | [2.6](/filings/0001086222-24-000199.md) | [2.6](/filings/0001086222-24-000216.md) | [2.6](/filings/0001086222-26-000022.md) | [2.4](/filings/0001086222-25-000149.md) | [2.0](/filings/0001086222-25-000218.md) | [2.2](/filings/0001086222-25-000256.md) | [2.3](/filings/0001086222-26-000086.md) | [2.1](/filings/0001086222-26-000058.md) | [4.7](/filings/0001086222-26-000086.md) |
| Total assets | $bn | [9.6](/filings/0001086222-23-000285.md) | [9.9](/filings/0001086222-25-000028.md) | [9.9](/filings/0001086222-24-000148.md) | [10.1](/filings/0001086222-24-000199.md) | [10.2](/filings/0001086222-24-000216.md) | [10.4](/filings/0001086222-26-000022.md) | [10.0](/filings/0001086222-25-000149.md) | [10.5](/filings/0001086222-25-000218.md) | [10.8](/filings/0001086222-25-000256.md) | [11.5](/filings/0001086222-26-000086.md) | [11.6](/filings/0001086222-26-000058.md) | [15.1](/filings/0001086222-26-000086.md) |
| Current liabilities | $bn | [0.8](/filings/0001086222-23-000285.md) | [0.8](/filings/0001086222-25-000028.md) | [0.8](/filings/0001086222-24-000148.md) | [1.9](/filings/0001086222-24-000199.md) | [2.0](/filings/0001086222-24-000216.md) | [2.1](/filings/0001086222-26-000022.md) | [2.0](/filings/0001086222-25-000149.md) | [0.9](/filings/0001086222-25-000218.md) | [1.0](/filings/0001086222-25-000256.md) | [1.0](/filings/0001086222-26-000086.md) | [1.0](/filings/0001086222-26-000058.md) | [2.8](/filings/0001086222-26-000086.md) |
| Total liabilities | $bn | [5.3](/filings/0001086222-23-000285.md) | [5.3](/filings/0001086222-25-000028.md) | [5.3](/filings/0001086222-24-000148.md) | [5.3](/filings/0001086222-24-000199.md) | [5.4](/filings/0001086222-24-000216.md) | [5.5](/filings/0001086222-26-000022.md) | [5.4](/filings/0001086222-25-000149.md) | [6.1](/filings/0001086222-25-000218.md) | [6.1](/filings/0001086222-25-000256.md) | [6.5](/filings/0001086222-26-000086.md) | [6.7](/filings/0001086222-26-000058.md) | [10.3](/filings/0001086222-26-000086.md) |
| Shareholders' equity | $bn | [4.3](/filings/0001086222-24-000216.md) | [4.6](/filings/0001086222-26-000022.md) | [4.6](/filings/0001086222-25-000218.md) | [4.8](/filings/0001086222-25-000256.md) | [4.8](/filings/0001086222-25-000256.md) | [4.9](/filings/0001086222-26-000086.md) | [4.6](/filings/0001086222-26-000086.md) | [4.5](/filings/0001086222-26-000086.md) | [4.7](/filings/0001086222-25-000256.md) | [5.0](/filings/0001086222-26-000086.md) | [4.9](/filings/0001086222-26-000086.md) | [4.7](/filings/0001086222-26-000086.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [359 d](/filings/0001086222-24-000216.md) | [389 d](/filings/0001086222-26-000022.md) | [352](/filings/0001086222-25-000149.md) | [431 d](/filings/0001086222-25-000218.md) | [393 d](/filings/0001086222-25-000256.md) | [344 d](/filings/0001086222-26-000022.md) | [251](/filings/0001086222-26-000058.md) | [459 d](/filings/0001086222-26-000086.md) | [442 d](/filings/0001086222-25-000256.md) | [367 d](/filings/0001086222-26-000022.md) | [313](/filings/0001086222-26-000058.md) | [326 d](/filings/0001086222-26-000086.md) |
| Capital expenditure | $m | [134 d](/filings/0001086222-24-000216.md) | [70.4 d](/filings/0001086222-26-000022.md) | [93.8](/filings/0001086222-25-000149.md) | [91.0 d](/filings/0001086222-25-000218.md) | [113 d](/filings/0001086222-25-000256.md) | [92.9 d](/filings/0001086222-26-000022.md) | [118](/filings/0001086222-26-000058.md) | [146 d](/filings/0001086222-26-000086.md) | [113 d](/filings/0001086222-25-000256.md) | [132 d](/filings/0001086222-26-000022.md) | [102](/filings/0001086222-26-000058.md) | [145 d](/filings/0001086222-26-000086.md) |
| Share repurchases | $m | [113 d](/filings/0001086222-24-000216.md) | [54.9 d](/filings/0001086222-26-000022.md) | [125](/filings/0001086222-25-000149.md) | [128 d](/filings/0001086222-25-000218.md) | [166 d](/filings/0001086222-25-000256.md) | [138 d](/filings/0001086222-26-000022.md) | [500](/filings/0001086222-26-000058.md) | [300 d](/filings/0001086222-26-000086.md) | [0.0 d](/filings/0001086222-25-000256.md) | [0.0 d](/filings/0001086222-26-000022.md) | [206](/filings/0001086222-26-000058.md) | [410 d](/filings/0001086222-26-000086.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [159](/filings/0001086222-23-000285.md) | [156](/filings/0001086222-24-000148.md) | [153](/filings/0001086222-24-000199.md) | [155](/filings/0001086222-24-000216.md) | [157](/filings/0001086222-25-000149.md) | [154](/filings/0001086222-25-000218.md) | [153](/filings/0001086222-25-000256.md) | [151](/filings/0001086222-26-000058.md) | [145](/filings/0001086222-26-000086.md) | [145](/filings/0001086222-25-000256.md) | [150](/filings/0001086222-26-000058.md) | [154](/filings/0001086222-26-000086.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 143,716,609 at 2026-08-03, from the cover of the [10-Q filed 2026-08-07](/filings/0001086222-26-000086.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.